Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus — PhagoPied

Diabetic Foot Clinical Trial

Official title:
Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial

Status Not yet recruiting

Clinical Trial Summary

The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.

Clinical Trial Description

The secondary objectives of this study are: A. To compare the two study arms in terms of treatment safety and tolerance throughout the study. B. To compare the two study arms in terms of further changes in wound healing at weeks 2, 4, 6, 8, 10, 12. C. To describe the changes in the resistance and virulence of S. aureus (if present in the wound) from baseline to week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed. D. To describe in the two study arms the antibiotic resistance status of other bacteria isolated from wounds at week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed. E. To describe in the two study arms changes in wound microbiota from baseline to week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed. F. To describe the production of anti-phage antibodies during the topical treatment: baseline and week 4, at modification of the first-line treatment or new antibiotic prescription (if any), and at week 12. G. Creation of a biobank for future ancillary studies (including, but not limited to, cytokine levels and cellular immune responses): days 0 and week 4, as well as week 12. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02664740
Study type	Interventional
Source	Centre Hospitalier Universitaire de Nimes
Contact	Albert Sotto, MD, PhD
Phone	+33.(0)6.09.56.66.55
Email	albert.sotto@chu-nimes.fr
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	June 1, 2022
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06154915` - Immune Cells in Diabetic Chronic Foot Ulcers
Completed	`NCT04624516` - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence	N/A
Not yet recruiting	`NCT06278935` - Lifestyle Tailored Offloading for Diabetic Foot Ulcers	N/A
Completed	`NCT02373592` - Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer	N/A
Active, not recruiting	`NCT01903044` - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating	Phase 1/Phase 2
Completed	`NCT02092870` - Adipose Derived Regenerative Cellular Therapy of Chronic Wounds	Phase 2
Completed	`NCT01212120` - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections	N/A
Completed	`NCT00402727` - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection	Phase 3
Recruiting	`NCT04085705` - The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
Completed	`NCT04054804` - Digital Foot Check by Using the D-Foot, a New Software
Completed	`NCT04480801` - The Effect of Thermal Evaluation in Prevention of Diabetic Foot Ulcer	N/A
Not yet recruiting	`NCT04537676` - Patient Empowerment Study
Recruiting	`NCT04564443` - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot	N/A
Recruiting	`NCT05974592` - The Effect of Nurse-Led Diabetic Foot Self-Management Training Program	N/A
Not yet recruiting	`NCT04630795` - ViscoTurf - Preventing Secondary Diabetic Foot Ulceration.
Not yet recruiting	`NCT05431660` - Diabetic Foot School and Biomechanics	N/A
Completed	`NCT05101473` - Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study	N/A
Completed	`NCT05123157` - Pattern and Type of Amputation and Mortality Rate Associated With Diabetic Foot in Jeddah, Saudi Arabia: A Retrospective Cohort Study
Enrolling by invitation	`NCT05043636` - Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
Completed	`NCT03254095` - Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.